Insights

Gathering insights about Innovent…

Similar companies to Innovent

Innovent Tech Stack

Innovent uses 8 technology products and services including WP Rocket, DreamWeaver, Google Fonts API, and more. Explore Innovent's tech stack below.

WP Rocket
Caching
DreamWeaver
Editors
Google Fonts API
Font Scripts
Google Maps
Maps
Yoast SEO
Search Engines
Material Design Lite
UI Frameworks
Gravity Forms
Web Platform Extensions
Nginx
Web Servers

Media & News

Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of hypertension.
Nov 09, 2025 | www.prnewswire.com
Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
SAN FRANCISCO and SUZHOU, China , Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that pre-clinical study results of IBI3011 (IL-1RAP monoclonal antibody) and IBI3034 (TACI/BCMA chimeric fusion protein) were showcased at American College of Rheumatology (ACR) Annual Meeting 2025. Details are listed below: Title: IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model (IBI3011) Abstract Number : 0082 Presentation Form: Poster Time: October 26, 2025 10:30 AM – 12:30 PM (CT) Presenter: Dr. Hongling Tian IBI3011 is an innovative humanized monoclonal antibody blocking IL1α, IL1β, IL36 simultaneously, by targeting the extracellular domain of IL1RAP.
Nov 04, 2025 | www.prnewswire.com
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in Novo Nordisk's diabetes and weight-loss medicines.
Oct 27, 2025 | www.reuters.com
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with semaglutide in diabetes treatment SAN FRANCISCO and SUZHOU, China , Oct. 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the fourth Phase 3 clinical trial DREAMS-3 of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist, has met its primary endpoint. The results demonstrated that, in Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide showed superior efficacy to semaglutide on the primary endpoint—the proportion of participants achieving HbA1c < 7.0% and ≥10% body weight reduction from baseline at week 32 (48.0 vs.
Oct 26, 2025 | www.prnewswire.com
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.
Oct 22, 2025 | www.wsj.com
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
China's Innovent Biologics said on Wednesday it had signed an $11.4 billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate cancer therapies.
Oct 21, 2025 | www.reuters.com
Innovent's weight-loss drug highlights China challenge for Novo, Lilly
Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction.
Sep 22, 2025 | www.reuters.com

Innovent's Email Address Formats

Innovent uses at least 2 format(s):

Innovent Email Formats	Example	Percentage
FLast@innovent.com	JDoe@innovent.com	58%
F.Last@innovent.com	J.Doe@innovent.com	21%
FirstL@innovent.com	JohnD@innovent.com	15%
First@innovent.com	John@innovent.com	6%
FirstL@innoventtech.com	JohnD@innoventtech.com	86%
First_Last@innoventtech.com	John_Doe@innoventtech.com	6%
FLast@innoventtech.com	JDoe@innoventtech.com	5%
First.Last@innoventtech.com	John.Doe@innoventtech.com	3%

Frequently Asked Questions

Where is Innovent's headquarters located?

Innovent's main headquarters is located at 107 Audubon Rd, Wakefield, MA 01880, US. The company has employees across 5 continents, including North AmericaEuropeAfrica.

What is Innovent's phone number?

You can contact Innovent's main corporate office by phone at

+1-978-538-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Innovent's stock symbol?

Innovent is a publicly traded company; the company's stock symbol is IVBXF.

What is Innovent's official website and social media links?

Innovent's official website is innovent.com and has social profiles on LinkedIn.

How much revenue does Innovent generate?

As of October 2025, Innovent's annual revenue is estimated to be $6M.

What is Innovent's SIC code NAICS code?

Innovent's SIC code is 5084 - Industrial Machinery and Equipment NAICS code is 333 - Machinery Manufacturing.

How many employees does Innovent have currently?

As of October 2025, Innovent has approximately 66 employees across 5 continents, including North AmericaEuropeAfrica. Key team members include Vice President Innovent: R. J.Owner: J. G.Regional Director Of Business Development: M. C. R.. Explore Innovent's employee directory with LeadIQ.

What industry does Innovent belong to?

Innovent operates in the Machinery Manufacturing industry.

What technology does Innovent use?

Innovent's tech stack includes WP RocketDreamWeaverGoogle Fonts APIGoogle MapsYoast SEOMaterial Design LiteGravity FormsNginx.

What is Innovent's email format?

Innovent's email format typically follows the pattern of FLast@innovent.com. Find more Innovent email formats with LeadIQ.

Innovent

Machinery ManufacturingUnited States51-200 Employees

Innovent is an engineering and manufacturing company delivering innovative product and service solutions to hygiene, aerospace, and industrial clients around the world.

Innovent is part of Standex International Corporation,  a diversified manufacturing company with operations in five product segments: Food Service Equipment Group, Air Distribution Products Group, Engineering Technologies Group, Engraving Group and Electronics and Hydraulics Group.